Department of Internal Medicine, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea , Uijeongbu-si, Gyeonggi-do , Korea,1.
Cancer Invest. 2013 Oct;31(8):516-21. doi: 10.3109/07357907.2013.826239. Epub 2013 Jul 31.
Considering the protumorigenic roles of interleukin-6 (IL-6) transsignaling, we assessed the serum levels of IL-6, soluble interleukin-6 receptor (sIL-6R), and soluble glycoprotein 130 (sgp130) in 143 patients with breast cancer. Serum levels of IL-6 were elevated with advanced T and N stage. Serum levels of sIL-6R were lower in patients with estrogen receptor-positive cancer. The median values of IL-6 and sgp130 did not differ between patients with recurrence and those without recurrence. However, higher serum levels of sIL-6R at diagnosis were associated with significantly shorter relapse-free survival in patients with estrogen receptor-positive breast cancer.
考虑到白细胞介素 6（IL-6）的转信号作用具有致癌作用，我们评估了 143 例乳腺癌患者的血清 IL-6、可溶性白细胞介素 6 受体（sIL-6R）和可溶性糖蛋白 130（sgp130）水平。随着 T 期和 N 期的进展，血清 IL-6 水平升高。雌激素受体阳性癌症患者的血清 sIL-6R 水平较低。复发和无复发患者的 IL-6 和 sgp130 的中位值无差异。然而，在雌激素受体阳性乳腺癌患者中，诊断时更高的血清 sIL-6R 水平与无复发生存期显著缩短相关。
